financial estimates
At JP Morgan, Myriad Genetics Says Q4 Test Volumes Disappointing, Firm Preps New Launches in 2025
Premium
The firm announced preliminary full-year 2024 revenue estimates that were slightly below expectations.
Executives also provided additional information on the firm's Q4 2024 financial performance.
The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.
Preliminary Earnings Roundup: Quanterix, Pacific Biosciences, Illumina
Life science tools companies Quanterix, Pacific Biosciences, and Illumina reported preliminary earnings results for 2024 on Tuesday.
Biodesix Preliminary Revenues up 39 Percent for Q4, 45 Percent for 2024
The company projected that it grew its revenues by double digits in both diagnostic testing and biopharma and other services.
Jul 8, 2024
MDxHealth Preliminary Q2 Revenues up 32 Percent
May 3, 2024
Fulgent Genetics Core Q1 Revenues Grow 1 Percent
Nov 8, 2023